- Главная
- Аналитика приложений
- AnticoagEvaluator
- AnticoagEvaluator Vs. Anticoagulation Manager
AnticoagEvaluator против Anticoagulation Manager Использование & Stats
Make well-informed decisions on antithrombotic therapy for your non-valvular AF patients with the updated AnticoagEvaluator.
Use the app to:
• Calculate a patient's renal function and risk of ischemic stroke, thromboembolism, and bleed
• Review ACC/AHA/HRS Guideline-driven therapy guidance for stroke prevention
• Generate individualized risk for antithrombotic therapy options based on individual clinical trials.
• Improve accurate use of DOACs with adjusted dosage based on prescribing information, fine-tuned for renal and other patient characteristics.
This app is based on SPARC Tool, developed by Peter Loewen, ACPR, Pharm.D., FCSHP, which can be viewed at www.sparctool.com
- Apple App Store
- Бесплатный
- Медицина
Рейтинг магазина
- -
The Anticoagulation Manager is a mobile application developed through the collaborative efforts of the CDC and the Georgia Institute of Technology. Since the determination of the correct type and dose of anticoagulant drugs can be challenging, this application is a resource for clinicians to appropriately order laboratory testing and choose anticoagulant drugs for the various indications. It gives clinicians evidence-based, accessible, and accurate information when prescribing anticoagulants to prevent and/or treat abnormal clotting states.
- Apple App Store
- Бесплатный
- Медицина
Рейтинг магазина
- -
AnticoagEvaluator vs. Anticoagulation Manager ranking comparison
Compare AnticoagEvaluator ranking trend in the past 28 days vs. Anticoagulation Manager
Rank
Нет данных
Рейтинг AnticoagEvaluator против Anticoagulation Manager в сравнении по странам
Сравните динамику рейтинга AnticoagEvaluator за последние 28 дней с динамикой рейтинга Anticoagulation Manager.
Нет данных для отображения
Сравните данные с любым сайтом, воспользовавшись бесплатной пробной версией
AnticoagEvaluator VS.
Anticoagulation Manager
декабрь 19, 2024